¦^­º­¶|Á{Âå©Ò|Âå¬ã©Ò|¥Í¤Æ¾Ç¬ì|°ªÂå­º­¶|Ápµ¸§Ú­Ì| English
Home | GICM| GIM | BioChem | KMU | ContactUs | Chinese

°ª¶¯Âå¾Ç¤j¾ÇÂå¾Ç°|Á{§ÉÂå¾Ç¬ã¨s©Ò

¶Àªü±ö¦Ñ®v¹êÅç«Ç

 

¹êÅç«Ç¤¶²Ð
¹êÅç«Ç¦¨­û
¹êÅç«Ç¸ê·½
¶}³]½Òµ{
ºô¸ô¸ê·½
§Ú­Ìªº·Ó¤ù
KMU club


³Ì·s®ø®§

±b¸¹:

±K½X:

 

gmeeting

QR code


¹êÅç«Ç¤¶²Ð

¬ã¨s­«ÂI
¥»¹êÅç«Ç¥D­n±´°QÂà¿ý¦]¤lCCAAT/enhancer binding protein delta (C/EBPdelta, C/EBP£_, CEBPD)¦b¥¿±`»PÀù¯g²Ó­M¤¤¹ï¤£¦PÀô¹Ò¦]¤l¤Î¤º¥Í©ÊÀ£¤O©Ò°Ñ»Pªº°T®§¶Ç»¼¸ô®|¤§½Õ±±¡A¥H¶i¦ÓÁA¸ÑC/EBPdelta©Ò§êºt¤§¨¤¦â¤Î§@¥Î¾÷Âà¡C
¬ã¨s¤è¦V
¥»¹êÅç«Ç¥HÂà¿ý¦]¤lCCAAT/enhancer binding protein delta (C/EBPdelta, C/EBP£_, CEBPD)¬°¥DÃD¬ã¨s¨ä¦b
1.¦Ñ¹«­F­LÅÖºû¥À²Ó­M(mouse embryonic fibroblasts, MEFs)¤¤ºûÅ@°ò¦]Å駹¾ã©Êªº¾÷¨î±´°Q¡F
2.²Ó­M¤¤»¤¾É²Ó­M­ä¤`¤Î½Õ¸`²Ó­M¶g´Áªº¾÷¨î±´°Q;
3¤HÃþ»H¯Öªc§¿¤W¥ÖÀù²Ó­M®èªº§ÜÃĩʪº¥\¯à¤Î¨¤¦â§êºt;
4.ªvÀøÀù²Ó­M§ÜÃĩʪº¤ÑµMÃĪ«¶}µo¤Î¨ä¾÷Âध±´°Q¡C
´Á±æ¯à¦b¥¼¨Ó±N©Ò±o¨ìªºª¾ÃÑÀ³¥Î¨ì¤HÃþ¯e¯f©MÀù¯gªº¹w¨¾¡B¶EÂ_¤ÎªvÀø¡C

°õ¦æ¤§±MÃD¬ã¨s­pµe (before 2012)

7 . ­pµe¦WºÙ¡Gµû¦ôCEBPD½Õ±±°T®§¸ô®|¦bªc§¿¤W¥ÖÀùªvÀøªº¥i¦æ©Ê:µÛ­«¦b§ÜÃĩʪº¤À¤l¾÷Âà±´°Q
(2011/8/1~2012/7/31)
­pµe½s¸¹¡GNSC100-2320-B-037-013- (°ê¬ì·|)
°Ñ»P¤u§@¡G¥D«ù¤H
8. ­pµe¦WºÙ¡G±qÀù¯gÂಾ»¤¾É¹Ï¤¤ÃѧO¥¢½Õªº¥Íª«³~®|¡V¥H«e¦C¸¢Àù¬°¨Ò
(2012/8/1~2013/7/31)
­pµe½s¸¹¡GNSC101-2221-E-231-030- (°ê¬ì·|)
°Ñ»P¤u§@¡G¦@¦P¥D«ù¤H
9.­pµe¦WºÙ¡GCEBPD°Ñ»P¦b»H¯ÖÀù­PÀù¾÷Â઺±´°Q
(2012/12/1~2013/12/31)
­pµe½s¸¹¡GKMU-M102008 (°ª¶¯Âå¾Ç¤j¾Ç¸É§U±Ð®v±MÃD¬ã¨s­pµe)
°Ñ»P¤u§@¡G¥D«ù¤H
10.­pµe¦WºÙ¡GPTEN°Ñ»PCEBPD¤¶¾É¶¶¹`ªºÃĪ«§@¥Î¾÷Âà±´°Q¤Î¨äÀ³¥Î
(2013/8/1~2014/7/31)
­pµe½s¸¹¡GNSC 102-2320-B-037-026- (°ê¬ì·|)
°Ñ»P¤u§@¡G¥D«ù¤H
11.­pµe¦WºÙ¡GCEBPD °Ñ»Pªc§¿¤W¥ÖÀù¤ÆÀøÃĪ«§@¥Î¤Î§ÜÃĩʵo®iªº¾÷Âà¤ÎÀ³¥Î: °w¹ïcisplatin-AKT-CEBPD-PTEN §@¥Î¸ô®|¤§¬ã¨s (2014/8/1~2015/7/31)
­pµe½s¸¹¡GNSC 103-2320-B-037 -029 - (¬ì§Þ³¡)
°Ñ»P¤u§@¡G¥D«ù¤H
12 .­pµe¦WºÙ¡Gcyclooxygenase§í¨î¾¯¦b¤HÃþªc§¿¤W¥Ö²Ó­MÀù¤Î¶¶¹`§ÜÃĮ褧À³¥Î¤Î¾÷Âà±´°Q
(2016/1/1~2016/12/31)
­pµe½s¸¹¡GKMU-M105002 (°ª¶¯Âå¾Ç¤j¾Ç¸É§U
±Ð®v±MÃD¬ã¨s­pµe)
°Ñ»P¤u§@¡G¥D«ù¤H
13. ­pµe¦WºÙ¡G¤j°ª¶¯¥«°Ïµn­²¼ö¯f´C°Aªø´Á©wÂIÆ[´ú»P½Õ¬d¤§¬ã¨s-«n°ª¶¯°Ï(2017/5/1~2017/12/31)
­pµe½s¸¹¡G NHRI-106A1-MRCO-1017174 (106¦~«×¡u°A´C¶Ç¬V¯f¨¾ªv¬ã¨s»E¸¨¤§¦X§@Åé¨t¡v­pµe)
°Ñ»P¤u§@¡G¥D«ù¤H
14. ­pµe¦WºÙ¡G«n°ª¶¯°Ïµn­²¼ö¯f´C°Aªø´Á©wÂIÆ[´ú»P½Õ¬d¤§¦Aºë½o¤Æ©µÄò¬ã¨s(2018/1/1~2018/12/31)
­pµe½s¸¹¡G NHRI-07A1-MRPP33-035 (107¦~«×¡u°A´C¶Ç¬V¯f¨¾ªv¬ã¨s»E¸¨¤§¦X§@Åé¨t¡v­pµe)
°Ñ»P¤u§@¡G¥D«ù¤H

15. ­pµe¦WºÙ¡GCEBPD»P¨ä¼Ðªº·L®Ö¿}®Ö»Ä¦bªc§¿¤W¥ÖÀùªº¶iµ{¤Î§ÜÃĩʵo®iªº¨¤¦â¤Î¾÷Âà±´°Q(2018/8/1~2019/07/31)
­pµe½s¸¹¡GMOST 107-2314-B-037-014 - (¬ì§Þ³¡)
°Ñ»P¤u§@¡G¥D«ù¤H
16. ­pµe¦WºÙ¡G¶}µo©M«Ø¥ß´C°A±aµn­²¼ö¯f¬r¤§¤À¤lÀË´ú¬yµ{ (2019/1/1~2019/12/31)
­pµe½s¸¹¡G NHRI-MR-108-CO-10 (108¦~«×¡u°A´C¶Ç¬V¯f¨¾ªv¬ã¨s»E¸¨¤§¦X§@Åé¨t¡v­pµe)
°Ñ»P¤u§@¡G¥D«ù¤H

17. ­pµe¦WºÙ¡GCEBPD³z¹L½Õ±±·L®Ö¿}®Ö»ÄmiR-17-92 cluster¦b¤W/ªc§¿¤W¥ÖÀùªº¶iµ{¤Î§ÜÃĩʵo®iªº¾÷Âà±´°Q (2019/08/1~2022/07/31)
­pµe½s¸¹¡GMOST 108-2314-B-037-031-MY3 (¬ì§Þ³¡)
°Ñ»P¤u§@¡G¥D«ù¤H

18. ­pµe¦WºÙ¡G±´¯Á¥hªx¯À¤Æ»Ã¯ÀUSP2a°Ñ»P¦bªc§¿¤W¥ÖÀù¥Í¦¨¤Î¶¶¹`¤ÏÀ³ªº¼Ðªº³J¥Õ
(2023/1/1~2023/12/31)
­pµe½s¸¹¡GKMU-M112020 (°ª¶¯Âå¾Ç¤j¾Ç¸É§U±Ð®v±MÃD¬ã¨s­pµe)
°Ñ»P¤u§@¡G¥D«ù¤H



¬ã¨s¦¨ªG¡G·|ij¾À³øµoªí(posters)(click)

¬ã¨s¦¨ªG¡G±M§Q
1.±M§Q¦WºÙ: ºµªG»Ä­l¥Íª«¤Î¨äÂåÅ@²Õ¦Xª«
µo©ú¤H: ªL©¾¨k¡BÒ\¬Ó³ó¡B¶Àªü±ö¡BÃQ¦Ê¸S¡BÃCª÷»ñ¡B«J¦Û»Í¡B·¨¥@¸s¡B»Z¥Ã§µ¡B¯Î²ì»x
ÃҮѸ¹½X: I386415 (¤¤µØ¥Á°ê)
2.±M§Q¦WºÙ: §@¥Î©ó·L¤pºÞ§ÜÀùÃĪ«2',5'-dimethoxychalcone­l¥Íª«¤§¦X¦¨»P¬¡©Êµû¦ô
µo©ú¤H: ªL©¾¨k¡BÒ\¬Ó³ó¡B¶Àªü±ö¡B«J¦Û»Í¡B·¨¥@¸s¡B»Z¥Ã§µ¡B±i«Ø°ê
±M§QÃҮѸ¹½X: I419687 (¤¤µØ¥Á°ê)
3.±M§Q¦WºÙ: §Ü¤HÃþªc§¿¤W¥ÖÀù¤§­»®Û¶WÁ{¬ÉµÑ¨úª«¡B»s³Æ¤èªk¤Î¥Î³~
µo©ú¤H: §õ§ÓùÚ¡B¶Àªü±ö¡B³¯¤¤¤@¡B³s°öºa¡B¼Bã´f
±M§QÃҮѸ¹½X: I448295 (¤¤µØ¥Á°ê)
4.±M§Q¦WºÙ:The anti-human urothelial carcinoma of supercritical carbon dioxide extract of cinnamomum subavenium, and the preparation process and uses
µo©ú¤H: §õ§ÓùÚ¡B¶Àªü±ö¡B³¯¤¤¤@¡B³s°öºa¡B¼Bã´f
(Jih-Heng Li, A-Mei Huang, Chung-Yi Chen, Pei-Jung Lien, Chiung-Hui Liu)
±M§QÃҮѸ¹½X:US8,669,377B2 (¬ü°ê)
5. ±M§Q¦WºÙ: ºµªG»Ä­l¥Íª«¤Î¨äÂåÅ@²Õ¦Xª«
µo©ú¤H: ªL©¾¨k¡BÒ\¬Ó³ó¡B¶Àªü±ö¡BÃQ¦Ê¸S¡BÃCª÷»ñ¡B«J¦Û»Í¡B·¨¥@¸s¡B»Z¥Ã§µ¡B¯Î²ì»x
ÃҮѸ¹½X: US 8729055B2 (¬ü°ê)
6.±M§Q¦WºÙ: 18£]-¥Ì¯ó¦¸»Ä­l¥Íª«¤Î¨ä¥Î³~
µo©ú¤H: ªL©¾¨k¡BªL³Í°¶¡B¶Àªü±ö¡B«J¦Û»Í¡B·¨¥@¸s¡B»Z¥Ã§µ¡B±i«Ø°ê
ÃҮѸ¹½X: I424839 (¤¤µØ¥Á°ê)
7.±M§Q¦WºÙ: Derivative of 18£]-glycyrrhetinic acid APT to suppress cancer cells
µo©ú¤H: ªL©¾¨k¡BªL³Í°¶¡B¶Àªü±ö¡B«J¦Û»Í¡B·¨¥@¸s¡B»Z¥Ã§µ¡B±i«Ø°ê
ÃҮѸ¹½X: US 8,686,178 B2 (¬ü°ê)

¬ã¨s¦¨ªG¡G´Á¥Z½×¤åµoªí (before 2013 #1~28)

No.
Title
Journal
IF and ranking
29
Lin, KW, Huang, AM, Yang, SC*, Weng, JR, Hour, TC, Pu, YS, and Lin, CN*. Cytotoxic and antioxidant constituents from Garcinia subelliptica. (¥þ¤å) Food Chemistry. 2012.
135 (2): 851-859

IF:3.655
ranking: 3/71 (2011)

30
Lin, KW, Lin, ZY, Huang, AM, Weng, JR, Yen, MH, Yang, SC*, Lin, CN*. Lantabetulic Acid Derivatives Induce G1 Arrest and Apoptosis in Human Prostate Cancer Cells. (¥þ¤å) Archiv der Pharmazie. 2014. 347(1): 42-53  IF: 1.54, ranking: 69/152 (2012)
31
Kao, YT, Hsu, WC, Hu, HT, Hsu, SH, Lin, CS, Chiu, CC, Lu, CY, Hour, TC, Pu, YS and Huang, AM*. Involvement of p38 MAPK in acquired gemcitabine-resistant human urothelial carcinoma sublines. (¥þ¤å) KAOHSIUNG J MED SCI. 2014. 30(7):323-330. IF 0.502, ranking: 104/121 (2012)
32
Hour, TC, Chung, SD, Kang, WY, Lin, YC, Chuang, SJ, Huang, AM, Wu, WJ, Huang, SP, Huang, CY, and Pu YS*. EGFR mediates docetaxel-resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). (¥þ¤å) Arch Toxicol. 2015. 89(4):591-605.

IF 5.215, ranking: 6/85 (2012)

 

33
Lin, KW, Huang, AM*, Lin, CC, Chang, CC, Hsu, WC, Hour, TC, Pu, YS , and Lin, CN*. Anti-cancer effects of ursane triterpenoid as a single agent and in combination with cisplatin in bladder cancer.(¥þ¤å) EUROPEAN JOURNAL OF PHARMACOLOGY. 2014. 740:742-51 (*co-correspondence)

IF 2.592, ranking: 105/261 (2012)

 

34
Wu CM, Lin KW, Teng CH, Huang AM, Chen YC, Yen MH, Wu WB, Pu YS, Lin CN*. 2014. Chalcone derivatives inhibit human platelet aggregation and inhibit growth in human bladder cancer cells. (¥þ¤å) Biol Pharm Bull. 2014. 37(7):1191-8. IF 1.849, ranking: 163/261 (2012)
35 Yeh HC, Huang CN, Li CC, Chang LL, Lin HH, Ke HL, Huang AM, Liang PI, Li CF*, Wu WJ*. Overexpression of PTP4A3 is associated with metastasis and unfavorable prognosis in bladder cancer. (¥þ¤å) World J Urol. 2016. 34(6): 835-46. IF 2.666, ranking: 23/78 (2013)
36 Lin KW, Maitraie D, Huang AM, Wang JP, Lin CN*. Triterpenoids and an alkamide from Ganoderma tsugae. (¥þ¤å) Fitoterapia. 2016. 108:73-80.

IF 2.345, ranking: 130/255 (2013)

37 Lin, SR, Yeh, HC, Wang, WJ, Ke, HL, Lin, HH, Hsu, WC, Chao, SY, Hour, TC, Wu, WJ, Pu, YS and Huang, AM*. MiR-193b Mediates CEBPD-induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells. (¥þ¤å) J Cell Biochem. 2017. 118(6):1563-1573. IF 3.446, ranking 101/289 (2015)
38 Huang, AM, Lin, KW, Lin, WH, Wu, LH, Chang, HC, Ni, C, Wang, DL, Hsu, HY, Su, CL, Shih, C. 1-Hydroxy-3-[(E)-4-(piperazine-diium)but-2-enyloxy]-9,10-anthraquinone ditrifluoroactate induced autophagic cell death in human PC3 cells. (¥þ¤å) Chem Biol Interac. 2018. 281:60-68. IF 3.296 (2018)
39 Hsu, WC, Lee, YC, Liang, PI, Chang, LL, Huang, AM, Lin, HH, Wu, WJ, Li, CC, Li, WM, Jhan, JH, and Ke, HL. CSF-1 Overexpression Predicts Poor Prognosis in Upper Tract Urothelial Carcinomas. (¥þ¤å) Disease Markers. 2019. 2019: 2724948. IF 2.761 (2019)
40 Hsu, WC, Li, WM, Lee, YC, Huang, AM, Chang, LL, Lin, HH, Wu, WJ, Li, CC, Liang, PI, Ke, HL. MicroRNA-145 Suppresses Cell Migration and Invasion in Upper Tract Urothelial Carcinoma by Targeting ARF6. (¥þ¤å) FASEB J. 2020. 34(4):5975-5992. IF 5.3911 (2019)
41 Lim, LM, Kung, LF, Kuo, MC, Huang, AM, and Kuo, HT*. Timing of mTORI usage and outcomes in kidney transplant recipients. (¥þ¤å) Int J Med Sci 2021. 18(5):1179-1184 IF 2.523 (2019)
42 Wu, YU, Lee, YC, L, WM, Hsu, WC, Lin, HH, Chang, LL, Huang, AM, Jhan, JH, Wu, WJ, Li, CC, Lee, HY, Yeh, HC and Ke, HL*.High Transaldolase 1 expression predicts poor survival of patients with upper tract urothelial carcinoma. (¥þ¤å) Pathol Int. 2021. 71(7):463-470. IF 2.534 (2020)
43 Chien, TM, Lee, HY, Singla, N, Margulis, V, Lotan, Y, Woldu, SL, Huang, CN, Li, CC, Ke, HL, Li, WM, Li, CY, Huang, AM, Yang, SF, Tu, HP, Wu, WJ, and Yeh, HC.*.Prognostic Factors for Contralateral Recurrence of Upper Tract Urothelial Carcinoma after Nephroureterectomy: A Large Multiregional Study. (¥þ¤å) Cancers. 2021. 13(23):5935. IF 6.639 (2021)
44 Jhan, JH, Hsu, WC, Lee, YC, Li, WM, Huang, AM, Lin, HH, Wang, CS, Wu, YR, Li, CC, Wu, WJ and Ke, HL*. MicroRNA-375-3p Suppresses Upper Tract Urothelial Carcinoma Cell Migration and Invasion via Targeting Derlin-1.(¥þ¤å)

Cancers. 2022.
14 (4): 880

IF 6.639 (2021)
45 Ke, HL, Lee, YC, Li, WM, Wang, CS, Hsu, WC, Lin, HH, Lee, YA, Jhan, JH, Li, CC, Yeh, HC, Wu, WJ and Huang, AM*. High Ubiquitin-Specific Protease 2a Expression Level Predicts Poor Prognosis in Upper Tract Urothelial Carcinoma. (¥þ¤å) Applied Immunohistochemistry & Molecular Morphology. 2022. 30(4):304-310 IF 2.085 (2021)
46 Yuan, CH, Hsu, WC, Huang, AM, Yuan, BC, Chen, IH, Hsu, CA, Chen, RF, Chu, YM, Lin, HH and Ke, HL*. MicroRNA-145-5p modulates Kruppel-like factor 5 and inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma. (¥þ¤å) BMC Molecular and Cell Biology. 2022. 23(1):28. IF 2.813 (2022)
47 Lim, LM, Chung, WY, Hwang , DY, Yu , CC, Ke, HL, Liang, PI, Lin, TW, Cheng, SM, Huang, AM*, and Kuo, HT*. Whole-Exome Sequencing Identified Mutational Profiles of Urothelial Carcinoma post Kidney Transplantation. (¥þ¤å) Journal of Translational Medicine. 2022. 20(1):324. IF 8.459 (2022)
48 Jhan, JH, Ke, HL, Lian, PI, Hsu, WC, Lee, YC, Lin, HH, Wu, YR, Huang, AM, Lee, HY, Yeh , HC, Wu, WJ, Li, CC, Li, WM*. High MRE11 Expression Level Predicts Poor Survival in Upper Tract Urothelial Carcinomas. (¥þ¤å) Applied Immunohistochemistry & Molecular Morphology. 2023. 31(2):94-100. IF 1.992 (2022)
49 Wang, CS, Lee, YC, Jhan, JH, Li, WM, Chang, LL, Huang, AM, Lin, HH, Wu, YR, Hsu, WC, Ke, HL*. MicroRNA-299-3p inhibits cell proliferation, motility, invasion and angiogenesis via VEGFA in upper tract urothelial carcinoma. (¥þ¤å) J. Gene Med . 2023 Dec 4:e3616. IF 4.152 (2023)
       
       
       

Tel (O): 07-3121101 ext. 2138-17, Fax : 07-3223075, E-mail: amhuang@kmu.edu.tw
Ápµ¸¦a§}:°ª¶¯¥«(807)¤T¥Á°Ï¤Q¥þ¤@¸ô100¸¹
°ª¶¯Âå¾Ç¤j¾ÇÂå¾Ç¬ã¨s¤j¼Ó416«Ç
¥»ºô¯¸³¡¤Àºô­¶¯À§÷¨Ó¦Û ªü²±ºô¯¸

Updated on January 15, 2024

All Rights Reserved!

free counters